WO2007059202A3 - Derives de pyrazolyluree utilisables dans le traitement du cancer - Google Patents
Derives de pyrazolyluree utilisables dans le traitement du cancer Download PDFInfo
- Publication number
- WO2007059202A3 WO2007059202A3 PCT/US2006/044322 US2006044322W WO2007059202A3 WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3 US 2006044322 W US2006044322 W US 2006044322W WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- treatment
- urea derivatives
- derivatives useful
- pyrazolyl urea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002629468A CA2629468A1 (fr) | 2005-11-15 | 2006-11-15 | Derives de pyrazolyluree utilisables dans le traitement du cancer |
EP06837652A EP1960394A2 (fr) | 2005-11-15 | 2006-11-15 | Derives de pyrazolyluree utilisables dans le traitement du cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73640005P | 2005-11-15 | 2005-11-15 | |
US60/736,400 | 2005-11-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007059202A2 WO2007059202A2 (fr) | 2007-05-24 |
WO2007059202A3 true WO2007059202A3 (fr) | 2007-08-09 |
Family
ID=38016517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/044322 WO2007059202A2 (fr) | 2005-11-15 | 2006-11-15 | Derives de pyrazolyluree utilisables dans le traitement du cancer |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1960394A2 (fr) |
CA (1) | CA2629468A1 (fr) |
WO (1) | WO2007059202A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
JP5511680B2 (ja) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリド[2,3−b]ピラジン−8−置換化合物及びその使用 |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
WO2010038086A2 (fr) * | 2008-10-02 | 2010-04-08 | Respivert Limited | Nouveaux composés |
AU2009326148B2 (en) | 2008-12-11 | 2014-05-08 | Respivert Limited | p38 MAP kinase inhibitors |
JP2012516843A (ja) * | 2009-02-02 | 2012-07-26 | インドコ レメディーズ リミテッド | ニトロピリジン誘導体の調製方法 |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
CN104945401B (zh) | 2010-02-01 | 2017-09-05 | 癌症研究技术有限公司 | Ip化合物及它们在治疗中的应用 |
WO2012003338A1 (fr) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet |
BR112013029201B1 (pt) | 2011-05-13 | 2022-08-09 | Array Biopharma Inc | Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
WO2014078322A1 (fr) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase |
WO2014078325A1 (fr) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
RS59286B1 (sr) | 2014-05-15 | 2019-10-31 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze |
EP3229836B1 (fr) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Anticoprs monoclonaux contre 'axl' |
WO2016135041A1 (fr) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Protéines de fusion et anticorps les contenant pour favoriser l'apoptose |
CN107056653B (zh) * | 2017-06-09 | 2019-07-09 | 丽珠医药集团股份有限公司 | 布南色林中间体对氟苯甲酰乙腈的合成方法 |
CA3140017A1 (fr) | 2019-07-19 | 2021-01-28 | Aurore HICK | Derives d'uree polyaromatiques et leur utilisation dans le traitement de maladies musculaires |
EP4029501A1 (fr) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032455A1 (fr) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees |
WO1999032106A1 (fr) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de raf kinase au moyen d'urees heterocycliques substituees |
WO2005110994A2 (fr) * | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer |
-
2006
- 2006-11-15 EP EP06837652A patent/EP1960394A2/fr not_active Withdrawn
- 2006-11-15 CA CA002629468A patent/CA2629468A1/fr not_active Abandoned
- 2006-11-15 WO PCT/US2006/044322 patent/WO2007059202A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032455A1 (fr) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees |
WO1999032106A1 (fr) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de raf kinase au moyen d'urees heterocycliques substituees |
WO2005110994A2 (fr) * | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer |
Non-Patent Citations (1)
Title |
---|
JACQUES DUMAS, HOLIA HATOUM-MOKDAD, ROBERT N. SIBLEY, ROGER A. SMITH, WILLIAM J. SCOTT, UDAY KHIRE, WENDY LEE ET AL.: "Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1559 - 1562, XP002434053 * |
Also Published As
Publication number | Publication date |
---|---|
CA2629468A1 (fr) | 2007-05-24 |
WO2007059202A2 (fr) | 2007-05-24 |
EP1960394A2 (fr) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007059202A3 (fr) | Derives de pyrazolyluree utilisables dans le traitement du cancer | |
WO2007064872A3 (fr) | Composes de l'uree utilises dans le traitement du cancer | |
WO2005110994A3 (fr) | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer | |
WO2006102504A3 (fr) | Combinaisons destinees au traitement de cancer | |
WO2007011962A3 (fr) | Traitement du cancer | |
WO2008098104A8 (fr) | Inhibiteurs de l'activité de akt | |
WO2007059008A3 (fr) | Indenoisoquinolines n-substituees et leur synthese | |
WO2005048948A3 (fr) | Derives d'uree en tant que modulateurs de la kinase | |
ZA200805163B (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer | |
WO2006086562A3 (fr) | Derives de phenylazetidinone | |
WO2007044084A3 (fr) | Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation | |
WO2007067781A3 (fr) | Inhibiteurs de proteines kinases | |
WO2007064945A3 (fr) | Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies | |
WO2008030883A3 (fr) | Traitement du cancer | |
WO2008021368A3 (fr) | Compositions et méthodes de neuroprotection | |
IL199151A (en) | Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits | |
WO2007079164A3 (fr) | Inhibiteurs de protéines kinases | |
TNSN07322A1 (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
WO2006004833A3 (fr) | Inhibiteurs de kinase a base de pyrrolotriazine | |
WO2006119510A3 (fr) | Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci | |
IL185484A0 (en) | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
WO2007109279A3 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
WO2007120333A3 (fr) | Inhibiteurs de kinase tétracycliques | |
WO2007146335A3 (fr) | Composés et compositions pour le traitement du cancer | |
WO2007016338A3 (fr) | Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2629468 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008541303 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006837652 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06837652 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |